The CLARITY trial looked at measurable residual disease negativity in 54 patients with relapsed or refractory chronic lymphocytic leukemia who received ibrutinib in combination with venetoclax.
Cancer Network spoke with Kelly Hunt, MD, professor and chair of the department of breast surgical oncology at the MD Anderson Cancer Center in Houston, about the role of surgery in metastatic breast cancer.
FoundationOne®Liquid can deliver reliable answers faster than tissue testing by analyzing 70 genes and reporting on microsatellite instability high (MSI-H) status from a simple blood draw.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: MultiMedia Healthcare
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA